Nanomab has a pipeline of four products for the treatment of a range of metastatic cancers with the first two products having undergone three separate human studies in China. NM-01 is scheduled to commence Phase 2 clinical studies later this year, whilst NM-02 is due to enter a European FIH therapeutic study towards the end of 2020.
- NM-01 (PD-L1 Lung Cancer, diagnostics)
- NM-02 (HER-2 positive Breast Cancer and Gastric Cancer, diagnostics and therapeutics)
- NM-03 (HER2 negative Breast Cancer, diagnostics and therapeutics)
- NM-04 (Colorectal and Cervical Cancer, diagnostics and therapeutics)